WallStreetZenWallStreetZen

NASDAQ: ADAP
Adaptimmune Therapeutics PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Be the first to know when Wall Street analysts revise their ADAP stock forecasts and price targets.

Forecast return on equity

Is ADAP forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.66%

Forecast return on assets

Is ADAP forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ADAP revenue forecast

What is ADAP's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$22.2M-63.17%
Avg 2 year Forecast
$21.5M-64.33%
ADAP's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ADAP revenue growth forecast

How is ADAP forecast to perform vs Biotechnology companies and vs the US market?
Company
45.96%
Industry
37.96%
Market
10.23%
ADAP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ADAP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ADAP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ADAP$0.90N/AN/A
CDT$2.99N/AN/A
QURE$4.71$17.80+277.92%Buy
CHRS$2.00$8.75+337.50%Strong Buy
LCTX$1.20$6.50+441.67%Strong Buy
View Top Biotech Stocks

Adaptimmune Therapeutics Stock Forecast FAQ

What is ADAP's revenue growth forecast for 2024-2025?

(NASDAQ: ADAP) Adaptimmune Therapeutics's forecast annual revenue growth rate of 45.96% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.96%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.23%.

Adaptimmune Therapeutics's revenue in 2024 is $60,281,000.On average, 1 Wall Street analysts forecast ADAP's revenue for 2024 to be $32,877,100,123, with the lowest ADAP revenue forecast at $32,877,100,123, and the highest ADAP revenue forecast at $32,877,100,123.

In 2025, ADAP is forecast to generate $31,840,434,804 in revenue, with the lowest revenue forecast at $31,840,434,804 and the highest revenue forecast at $31,840,434,804.

If you're new to stock investing, here's how to buy Adaptimmune Therapeutics stock.

What is ADAP's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ADAP) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is ADAP's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ADAP) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.